

1714
CASE 4-100-8303C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820012821US

Express Mail Label Number

October 4, 2002

Date of Deposit

#2/Jan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1714

SCHULER ET AL.

APPLICATION NO: 10/092,639

FILED: MARCH 7, 2002

FOR: USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND
XENOTRANSPLANTATIONAssistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/712,359 filed November 14, 2000, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765

Thomas R. Savitsky
Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: October 4, 2002

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
4-100-8303C/C1D1
APPLICATION NO.
10/092,639
APPLICANT
SCHULER ET AL.
FILING DATE
March 7, 2002

Group
1614



(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,362,718	11/8/94	Skotnicki et al.	514	63	4/18/94
	AB	5,516,781	5/14/96	Morris et al.	514	291	5/12/94
	AC	5,665,772	9/9/97	Cottens et al.	514	514	4/7/95
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
OCT - 8 2002
TECH CENTER 1800/2800
JAN 9 1 2003

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 94/09010	4/28/94	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 96/41807	12/27/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 568 310	11/3/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AP	EP 551 182	7/14/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 691 130	1/10/96	Europe			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Ikonen et al., "Sirolimus (Rapamycin) Halts and Reverses Progression of Allograft Vascular Disease in Non-Human Primates", Transplantation, Vol. 70, No. 6, pp. 969-975 (2000).
	AS	Matas et al., "Chronic Rejection", J. Am. Soc. Nephrol., Vol. 4, Suppl. 1, pp. S23-S29 (1994).
	AT	Kahan, "The Potential Role of Rapamycin in Pediatric Transplantation as Observed from Adult Studies", Pediatr Transplantation, Vol. 3, pp. 175-180 (1999).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-100-8303C/C1D1
APPLICATION NO.
10/092,639
APPLICANT
SCHULER ET AL.
FILING DATE
March 7, 2002

Group
1614



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Sadrani et al., "Chemical Modification of Rapamycin: The Discovery of SDZ RAD", Transplant. Proc., Vol. 30, pp. 2192-2194 (1998).
AB	Fellstrom et al., "Pathogenesis and Treatment Perspectives of Chronic Graft Rejection (CVR)", Immunological Reviews, No. 134, pp. 83-98 (1993).
AC	Meiser et al., "Effects of Cyclosporin, FK506, and Rapamycin on Graft-Vessel Disease", Lancet, Vol. 338, pp. 1297-1298 (1991).
AD	Gregory et al., "The Use of New Antiproliferative Immunosuppressants is a Novel and Highly Effective Strategy for the Prevention of Vascular Occlusive Disease", J. Heart Lung Transpl., Vol. 11, Pt. 11, p. 197 (1992).
AE	Morris et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplant. Proc., Vol. 23, No. 2, Suppl. 2, pp. 19-25 (1991).
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

RECEIVED
OCT - 8 2002
TO 1700 MAIL ROOM
JAN 31 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.